Disclosure under SEBI Takeover Regulations

Ref. No. CTL/SAST/26-27/00050/02 01 July 2026 1. Department of Corporate Services, BSE Limited Floor 25, P J Towers, Dalal Street, Mumbai - 400 001 2. National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 3. Gujarat Themis Biosyn Limited Plot No 69-C, GIDC Industrial Estate, Valsad District, Vapi, Gujarat, India, 396195 Sub: Disclosure under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Dear Sir/ Ma’am, Enclosed is a disclosure made by CTL Trusteeship Limited under Regulation 29 (1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (the “Takeover Code”). A debenture trust deed dated June 25, 2026, as amended from time to time (“Debenture Trust Deed”) has been entered into between, inter alia, OSS Software Solutions Labs Private Limited (as issuer) (“Issuer”) and CTL Trusteeship Limited (“Debenture Trustee”) for the purpose of issuance of debentures by the Issuer (“Debentures”). Pharmaceutical Business Group (India) Limited (“PBGIL”) holds 5,12,40,000 equity shares, constituting 47.02% of the issued and paid-up share capital as well as the total diluted share/ voting capital of Gujarat Themis Biosyn Limited (“Target Company”). Vividhmargi Investments Private Limited (“VIPL”) holds 49,49,500 equity shares in PBGIL, constituting 98.988% of the issued and paid-up share capital of PBGIL. In connection with the Debentures, the following encumbrances have been created by VIPL over the following shares of PBGIL, in favor of the Debenture Trustee, thereby resulting in an indirect encumbrance over shares of the Target Company: (a) pledge over 25,24,245 equity shares, constituting 51% of the issued and paid-up share capital as well as the total diluted share/ voting capital of PBGIL, with effect from June 29, 2026 (“Pledged Shares”); and (b) non-disposal undertaking over 21,57,855 equity shares, constituting 47.988% of the issued and paid-up share capital as well as the total diluted share/ voting capital of PBGIL. (collectively, “Shares”) This disclosure is being made by the Debenture Trustee in relation to the creation of indirect encumbrance by VIPL over the shares of the Target Company on account of creation of encumbrance (by way of pledge and non-disposal undertaking) over the Shares of PBGIL. Yours faithfully, For CTL Trusteeship Limited Authorised Signatory Name: Deesha Srikkanth Designation: Senior Vice President Place: Mumbai Date: 01 July 2026 Disclosure under Regulation 29(1) of SEBl (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Part-A - Details of the Acquisition Name of the Target Gujarat Themis Biosyn Limited Company (TC) Name(s) of the acquirer CTL Trusteeship Limited acting in its capacity as the debenture and Persons Acting in trustee under the Debenture Trust Deed (defined below) Concert (PAC) with the acquirer Whether the acquirer No belongs to Promoter/Promoter group Name(s) of the Stock BSE Limited and National Stock Exchange of India Limited Exchange(s) where the shares of TC are Listed Number % w.r.t. total % w.r.t. total share/voting diluted Details of the acquisition capital wherever share/voting as follows applicable(*) capital of the (**) Before the acquisition Refer to Note below Refer to Note below Refer to Note under consideration, below holding of acquirer along with PACs of: (a) Shares carrying voting rights (b) Shares in the Refer to Note below Refer to Note below Refer to Note nature of below encumbrance (pledge/ lien/ non- disposal undertaking/ others) (c) Voting rights (VR) Refer to Note below Refer to Note below Refer to Note otherwise than by below equity shares (d) Warrants/convertib Refer to Note below Refer to Note below Refer to Note le securities/any below other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) (e) Total (a+b+c+d) Refer to Note below Refer to Note below Refer to Note below Details of acquisition Refer to Note below Refer to Note below Refer to Note (a) Shares carrying below voting rights acquired (b) VRs acquired Refer to Note below Refer to Note below Refer to Note otherwise than by below equity shares (c) Warrants acquired Refer to Note below Refer to Note below Refer to Note by way of below encumbrance# (d) Shares in the Refer to Note below Refer to Note below Refer to Note nature of below encumbrance (pledge/ lien/non disposal undertaking/others (e) Total (a+b+c+/-d) Refer to Note below Refer to Note below Refer to Note below After the acquisition, holding of acquirer along with PACs of: (a) Shares carrying Refer to Note voting rights Refer to Note below Refer to Note below below (b) VRs otherwise Refer to Note below Refer to Note below Refer to Note than by equity below shares (c) Warrants/convertib Refer to Note below Refer to Note below Refer to Note le securities/any below other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition in the nature of encumbrance# (d) Shares in the Refer to Note below Refer to Note below Refer to Note nature of below encumbrance (pledge/ lien/non disposal undertaking/others (e) Total (a+b+c+d) Refer to Note below Refer to Note below Refer to Note below Mode of acquisition (e.g. There is no acquisition of any shares of the Target Company at open market/public present. This disclosure is being made considering creation of issue/rights encumbrance (by way of pledge and non-disposal undertaking) over issue/preferential the Shares, which may result in an indirect encumbrance on shares allotment/inter se of Target. transfer/encumbrance, etc.) Salient features of the Not applicable securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc. Date of acquisition of/ date In relation to encumbrance by way of: of receipt of intimation of allotment of shares / VR/ (a) pledge over 25,24,245 equity shares, constituting 51% of the warrants/convertible issued and paid-up share capital as well as the total diluted securities/ any other share/ voting capital of PBGIL - June 29, 2026; and instrument that entitles the acquirer to receive shares (b) non-disposal undertaking over 21,57,855 equity shares, in the TC. constituting 47.988% of the issued and paid-up share capital as well as the total diluted share/ voting capital of PBGIL. Equity share capital / total INR 10,89,65,265, comprising of 10,89,65,265 fully paid-up equity voting capital of the TC shares of INR 1/- each before the said acquisition Equity share capital/ total INR 10,89,65,265, comprising of 10,89,65,265 fully paid-up equity voting capital of the TC shares of INR 1/- each after the said acquisition Total diluted share/voting INR 10,89,65,265, comprising of 10,89,65,265 fully paid-up equity capital of the TC after the shares of INR 1/- each said acquisition Note #- 1. Pharmaceutical Business Group (India) Limited (“PBGIL”) holds 5,12,40,000 equity shares, constituting 47.02% of the issued and paid-up share capital as well as the total diluted share/ voting capital of Gujarat Themis Biosyn Limited (“Target Company”). Vividhmargi Investments Private Limited (“VIPL”) holds 49,49,500 equity shares in PBGIL, constituting 98.988% of the issued and paid-up share capital of PBGIL. 2. A debenture trust deed dated June 25, 2026, as amended from time to time (“Debenture Trust Deed”) has been entered into between, inter alia, OSS Software Solutions Labs Private Limited (as issuer) (“Issuer”) and CTL Trusteeship Limited (“Debenture Trustee”) for the purpose of issuance of debentures by the Issuer (“Debentures”). 3. In connection with the Debentures, the following encumbrances have been created by VIPL over the following shares of PBGIL, pursuant to a Pledge Agreement cum Non-Disposal Underta [Showing first 8,000 characters — download PDF for full document]